Osborne Clarke has advised Global Healthcare Company, Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), on its acquisition of the transfusion diagnostics unit of Novartis (NYSE: NVS, VX: NOVN).

The transaction was led by Partners Tomás Dagá and Raimon Grifols. Other partners involved were David Miranda for financing, Silvia Steiner for antitrust filing and Núria Martín for capital markets regulations. Associates Oscar Calsamiglia, Yana Sarkisova and Laura de la Cruz were involved in the legal due diligence process. This is the fourth deal that Osborne Clarke has advised Grifols on in the last 14 months. Others include:

• Advising Grifols on its 60% acquisition of Progenika, a biotechnology firm for €37 million.
• The buy-back of 4.4 million B shares from Cerberus, the American private equity group.
• The refinancing of Scranton enterprises, a major shareholder of Grifols.